谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

IMbassador250: A phase III trial in patients with metastatic castration-resistant prostate cancer (mCRPC) comparing atezolizumab plus enzalutamide vs enzalutamide alone

S. Gillessen Sommer,T. Powles, C. Drake,D. Rathkopf,S. Narayanan,M. Green,N. Leng,C. Schiff,C. Sweeney,K. Fizazi

European Urology Supplements（2018）

引用 1|浏览20
暂无评分
关键词
prostate cancer,atezolizumab,phase iii trial,castration-resistant
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要